Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proteogenomics | 9 | 2025 | 110 | 3.220 |
Why?
|
| Breast Neoplasms | 26 | 2025 | 2762 | 3.010 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2025 | 829 | 1.570 |
Why?
|
| Triple Negative Breast Neoplasms | 6 | 2025 | 277 | 1.430 |
Why?
|
| Cyclin-Dependent Kinase 6 | 4 | 2025 | 50 | 1.220 |
Why?
|
| Receptor, ErbB-2 | 6 | 2025 | 562 | 0.990 |
Why?
|
| Biomarkers, Tumor | 5 | 2025 | 1693 | 0.800 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2025 | 612 | 0.770 |
Why?
|
| Cyclin-Dependent Kinase 4 | 4 | 2025 | 67 | 0.740 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 22 | 0.670 |
Why?
|
| Receptors, Estrogen | 9 | 2025 | 829 | 0.630 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 136 | 0.620 |
Why?
|
| Neoadjuvant Therapy | 5 | 2025 | 407 | 0.610 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2018 | 13 | 0.580 |
Why?
|
| DNA Glycosylases | 1 | 2018 | 30 | 0.580 |
Why?
|
| Antigens, CD | 1 | 2020 | 441 | 0.580 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2021 | 271 | 0.580 |
Why?
|
| Endonucleases | 1 | 2018 | 56 | 0.570 |
Why?
|
| Calcium-Binding Proteins | 1 | 2018 | 334 | 0.520 |
Why?
|
| Proteomics | 4 | 2025 | 605 | 0.490 |
Why?
|
| Neurofibromin 1 | 4 | 2025 | 50 | 0.480 |
Why?
|
| Proteome | 4 | 2023 | 282 | 0.450 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 702 | 0.420 |
Why?
|
| Estrogen Receptor alpha | 4 | 2023 | 478 | 0.420 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 2145 | 0.400 |
Why?
|
| Aromatase Inhibitors | 4 | 2022 | 79 | 0.380 |
Why?
|
| Trastuzumab | 2 | 2025 | 154 | 0.380 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2012 | 408 | 0.370 |
Why?
|
| Drug Delivery Systems | 2 | 2012 | 232 | 0.370 |
Why?
|
| Protein Folding | 1 | 2011 | 222 | 0.340 |
Why?
|
| Bacterial Proteins | 3 | 2012 | 924 | 0.340 |
Why?
|
| Female | 28 | 2025 | 71503 | 0.300 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2009 | 173 | 0.290 |
Why?
|
| Humans | 36 | 2025 | 133373 | 0.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1353 | 0.270 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2025 | 249 | 0.250 |
Why?
|
| Proteins | 1 | 2011 | 1090 | 0.250 |
Why?
|
| Carboplatin | 2 | 2022 | 86 | 0.240 |
Why?
|
| Mitosis | 1 | 2025 | 205 | 0.230 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2022 | 93 | 0.220 |
Why?
|
| Computational Biology | 1 | 2009 | 887 | 0.210 |
Why?
|
| MCF-7 Cells | 3 | 2020 | 233 | 0.210 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 1915 | 0.210 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 1849 | 0.210 |
Why?
|
| Mutation | 6 | 2023 | 6343 | 0.210 |
Why?
|
| Tissue Array Analysis | 2 | 2020 | 143 | 0.200 |
Why?
|
| Prognosis | 6 | 2023 | 5044 | 0.200 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 20 | 0.200 |
Why?
|
| Circulating Tumor DNA | 1 | 2022 | 39 | 0.190 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 75 | 0.190 |
Why?
|
| Cell Proliferation | 4 | 2025 | 2559 | 0.180 |
Why?
|
| Mass Spectrometry | 1 | 2023 | 367 | 0.180 |
Why?
|
| Quinolines | 1 | 2022 | 115 | 0.180 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2025 | 541 | 0.170 |
Why?
|
| Cell Line, Tumor | 6 | 2025 | 3794 | 0.160 |
Why?
|
| Multienzyme Complexes | 2 | 2011 | 89 | 0.160 |
Why?
|
| Tamoxifen | 2 | 2020 | 377 | 0.160 |
Why?
|
| STAT1 Transcription Factor | 1 | 2020 | 77 | 0.160 |
Why?
|
| Up-Regulation | 2 | 2020 | 910 | 0.160 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2019 | 11 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2025 | 1013 | 0.160 |
Why?
|
| Gene Regulatory Networks | 2 | 2020 | 398 | 0.160 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2019 | 39 | 0.160 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2019 | 52 | 0.160 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 236 | 0.160 |
Why?
|
| Immune Tolerance | 1 | 2020 | 149 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 128 | 0.160 |
Why?
|
| Ki-67 Antigen | 3 | 2024 | 118 | 0.150 |
Why?
|
| Protein Kinases | 2 | 2020 | 340 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 2125 | 0.150 |
Why?
|
| DNA Repair | 2 | 2020 | 573 | 0.150 |
Why?
|
| Antitubercular Agents | 2 | 2011 | 265 | 0.140 |
Why?
|
| Gene Fusion | 1 | 2018 | 61 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 407 | 0.140 |
Why?
|
| Interferon-gamma | 1 | 2020 | 536 | 0.140 |
Why?
|
| MutL Proteins | 1 | 2017 | 19 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2020 | 361 | 0.140 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2017 | 35 | 0.140 |
Why?
|
| Heterografts | 1 | 2018 | 201 | 0.140 |
Why?
|
| Signal Transduction | 5 | 2025 | 4917 | 0.140 |
Why?
|
| Transcriptome | 2 | 2021 | 1135 | 0.130 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 401 | 0.120 |
Why?
|
| Gene Amplification | 1 | 2016 | 245 | 0.120 |
Why?
|
| Mice | 6 | 2025 | 18936 | 0.120 |
Why?
|
| Genomic Instability | 1 | 2016 | 245 | 0.110 |
Why?
|
| Animals | 8 | 2025 | 36222 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 1036 | 0.100 |
Why?
|
| Pyridines | 2 | 2025 | 250 | 0.100 |
Why?
|
| Piperazines | 2 | 2025 | 256 | 0.100 |
Why?
|
| Middle Aged | 7 | 2025 | 28985 | 0.100 |
Why?
|
| Protein Interaction Mapping | 2 | 2012 | 94 | 0.100 |
Why?
|
| Crowdsourcing | 1 | 2012 | 13 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 2 | 2025 | 676 | 0.090 |
Why?
|
| Subcellular Fractions | 1 | 2011 | 98 | 0.090 |
Why?
|
| Protein Structure, Quaternary | 1 | 2011 | 102 | 0.090 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 256 | 0.090 |
Why?
|
| Genome, Bacterial | 1 | 2012 | 212 | 0.090 |
Why?
|
| Postmenopause | 2 | 2024 | 155 | 0.090 |
Why?
|
| Protein Transport | 1 | 2011 | 389 | 0.080 |
Why?
|
| Disease | 1 | 2011 | 132 | 0.080 |
Why?
|
| Biomarkers | 1 | 2019 | 3415 | 0.080 |
Why?
|
| Mice, Nude | 2 | 2021 | 780 | 0.080 |
Why?
|
| Amino Acids | 1 | 2011 | 685 | 0.070 |
Why?
|
| GTP-Binding Proteins | 1 | 2009 | 187 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2022 | 1612 | 0.070 |
Why?
|
| Macrophages | 1 | 2012 | 697 | 0.070 |
Why?
|
| Cell Nucleus | 2 | 2020 | 689 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2023 | 2877 | 0.060 |
Why?
|
| Apoptosis | 2 | 2024 | 1928 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2009 | 708 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2020 | 5199 | 0.060 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2025 | 81 | 0.060 |
Why?
|
| DNA Damage | 2 | 2020 | 517 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2025 | 119 | 0.060 |
Why?
|
| Immunotherapy | 2 | 2021 | 750 | 0.060 |
Why?
|
| Genomics | 3 | 2020 | 1676 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 1313 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2019 | 1584 | 0.060 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 700 | 0.060 |
Why?
|
| Aged | 4 | 2025 | 21500 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2025 | 240 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2024 | 234 | 0.050 |
Why?
|
| Nitriles | 1 | 2024 | 155 | 0.050 |
Why?
|
| NFI Transcription Factors | 1 | 2023 | 54 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 93 | 0.050 |
Why?
|
| Purines | 1 | 2023 | 119 | 0.050 |
Why?
|
| Triazoles | 1 | 2024 | 142 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 1 | 2022 | 156 | 0.050 |
Why?
|
| Quinazolines | 1 | 2022 | 185 | 0.040 |
Why?
|
| APOBEC Deaminases | 1 | 2020 | 7 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 781 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 2020 | 85 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2020 | 105 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2023 | 361 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2020 | 34 | 0.040 |
Why?
|
| Co-Repressor Proteins | 1 | 2020 | 39 | 0.040 |
Why?
|
| British Columbia | 1 | 2019 | 11 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 1097 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2020 | 212 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 2020 | 107 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2020 | 356 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2021 | 302 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 7141 | 0.040 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2019 | 39 | 0.040 |
Why?
|
| ras Proteins | 1 | 2020 | 146 | 0.040 |
Why?
|
| Brazil | 1 | 2019 | 135 | 0.040 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2018 | 8 | 0.040 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2018 | 8 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2018 | 15 | 0.040 |
Why?
|
| Adult | 4 | 2021 | 31684 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2020 | 614 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 307 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 83 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 788 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2023 | 1072 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2020 | 505 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 714 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 453 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 9 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 471 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 399 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 348 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2020 | 1707 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2023 | 13103 | 0.030 |
Why?
|
| Survival Rate | 1 | 2021 | 2207 | 0.030 |
Why?
|
| Transfection | 1 | 2018 | 1095 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2246 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2019 | 1067 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1469 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 899 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2017 | 619 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1730 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 4760 | 0.020 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2011 | 15 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2018 | 3418 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2012 | 265 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2011 | 180 | 0.020 |
Why?
|
| Male | 2 | 2025 | 65592 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 2785 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 9923 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3960 | 0.020 |
Why?
|